Zymeworks Inc
ZYME22.720USD
+0.700+3.18%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.72BMarket Cap
LossP/E TTM
More Details of Zymeworks Inc Company
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Zymeworks Inc Info
Ticker SymbolZYME
Company nameZymeworks Inc
IPO dateJun 24, 2019
CEOGalbraith (Kenneth H)
Number of employees280
Security typeOrdinary Share
Fiscal year-endJun 24
Address108 Patriot Drive, Suite A
CityMIDDLETOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19709
Phone13022748744
Websitehttps://www.zymeworks.com/
Ticker SymbolZYME
IPO dateJun 24, 2019
CEOGalbraith (Kenneth H)
Company Executives of Zymeworks Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Other
47.56%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Other
47.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
51.31%
Investment Advisor
20.98%
Hedge Fund
18.80%
Research Firm
6.53%
Private Equity
2.79%
Individual Investor
1.24%
Venture Capital
0.28%
Sovereign Wealth Fund
0.27%
Pension Fund
0.25%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
333
74.80M
105.96%
--
2025Q4
404
76.14M
101.75%
-5.97M
2025Q3
390
74.41M
99.43%
-2.56M
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EcoR1 Capital, LLC
22.97M
30.69%
--
--
Nov 16, 2025
Rubric Capital Management LP
4.71M
6.29%
--
--
Sep 30, 2025
BVF Partners L.P.
3.94M
5.26%
-370.29K
-8.59%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.92M
5.23%
+295.26K
+8.15%
Sep 30, 2025
Redmile Group, LLC
3.71M
4.95%
-444.88K
-10.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
4.17%
+11.88K
+0.38%
Sep 30, 2025
The Vanguard Group, Inc.
2.15M
2.87%
-310.26K
-12.63%
Sep 30, 2025
Perceptive Advisors LLC
2.09M
2.79%
+815.39K
+63.94%
Sep 30, 2025
Vestal Point Capital, LP
1.76M
2.36%
+615.00K
+53.48%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
1.62M
2.16%
-40.50K
-2.44%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
2.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Micro-Cap ETF
0.18%
Federated Hermes MDT Small Cap Core ETF
0.15%
WisdomTree US SmallCap Quality Growth Fund
0.15%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.12%
View more
Tema Oncology ETF
Proportion2.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.99%
ProShares Ultra Nasdaq Biotechnology
Proportion0.24%
iShares Micro-Cap ETF
Proportion0.18%
Federated Hermes MDT Small Cap Core ETF
Proportion0.15%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.15%
SPDR S&P International Small Cap ETF
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
iShares Biotechnology ETF
Proportion0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
